According to the World Health Organization (WHO), cardiovascular disease (CVD) is the leading cause of death globally. Some of the risk factors for CVD include high cholesterol, hypertension and diabetes. Red yeast rice has been shown to help lower cholesterol and improve blood circulation, as well as positively impacting blood lipids, blood glucose and blood pressure. This Whitepaper by SunWay Biotech Co. Ltd. explores the potential of ANKASCIN® 568-R red yeast rice extract—which does not contain monacolin K (statin)—in heart health dietary supplement applications. • The CDC attributes one-quarter of American deaths annually to CVD, with no gender bias. • U.S. sales of red yeast rice dietary supplements were estimated at $49 million in 2015. • The U.S. heart health ingredient market is predicted to reach $15.2 billion by 2018 Source: Natural Products Insider
This year, we are going to exhibit at SupplySide West 2017 in Las Vegas during September 27-28. Here you will see our multi-functional dietary ingredients － ANKASCIN 568-R and Vigiis 101-LAB.
Interview from PharmaBoardRoom: George J. Lee, Ph.D. – Chairman; Tzu-Ming Pan, Ph.D – Vice Chairman and Chief Technology and Science Officer, SunWay Biotech, Taiwan
George Lee and Tzu-Ming Pan introduce SunWay Biotech’s groundbreaking red yeast rice extract, ANKASCIN® 568-R, which has been recognized as a New Dietary Ingredient by the US FDA. SunWay Biotech is now bringing this unique product onto the global stage and are considering developing a pharmaceutical product based on the same compounds.
2016 Taiwan-ASEAN Investment Strategy Partner Forum Held as Part of New Southbound Policy: Connect with ASEAN to Create New Business Opportunities
The Taiwan-ASEAN Investment Strategy Partner Forum, organized by the Ministry of Economic Affairs’s (MOEA) Department of Investment Services, was held at the Taipei International Conference Center today (the 13th).
Meet Us at SupplySide West 2016 in Las Vegas (USA) during October 6-7 and Hi Europe & Ni 2016 in Frankfurt (Germany) during November 29-December 1
This year, we are going to exhibit at SupplySide West 2016 in Las Vegas during October 6-7 and Hi Europe & Ni 2016 in Frankfurt during November 29-December 1. Here you will see our multi-functional dietary ingredients － ANKASCIN 568-R and Vigiis 101-Probiotic. ANKASCIN 568-R has been completed in aspects of health benefits, safety, legality, and identity for quality assurance. During the exhibitions, we will share the information on our New Dietary Ingredient document issued by the US FDA as well as two clinical trials on blood lipid and blood sugar control. You are very welcome to visit us at SupplySide West 2016 Hi Europe & Ni 2016 Las Vegas, USA Frankfurt, Germany […]
For the past nearly 20 years, ANKASCIN 568-R has been proven by 120+ publications to be effective in managing blood lipids, blood sugar, blood pressure, and improving symptoms of Alzheimer’s disease through many animal tests conducted by Professor Tzu-Ming Pan from National Taiwan University, Taiwan.
Meet Us at SupplySide West 2015 in Las Vegas during October 7-8 and Fi Europe & Ni 2015 in Paris during December 1-3
This year, we are going to exhibit at SupplySide West 2015 in Las Vegas during October 7-8 and Fi Europe & Ni 2015 in Paris during December 1-3. We will exhibit our multi-functional dietary ingredients － ANKASCIN 568-R and Vigiis 101-Probiotic. Remarkable advances have been made in the development of ANKASCIN 568-R. During the exhibitions, we will share the information on our New Dietary Ingredient approval by the US FDA as well as two clinical trials on blood lipid and blood sugar regulation. You are welcome to meet and visit us at stand # 1263 at SupplySide West 2015 and stand # 7B14 at Fi Europe & Ni 2015. Visit us for the innovative multi-functional dietary ingredients! We look forward to meeting you at SupplySide West 2015 and Fi Europe & Ni 2015.
With more than ten years of time-consuming and laborious efforts in manifesting the functions and safety, we proudly announce that our NEW red yeast rice extract (ANKASCIN 568-R) has been approved by the US FDA as an NEW DIETARY INGREDIENT (NDI, report # 855).